Tyrosine kinase inhibitors (TKIs) such as sorafenib, sunitinib, and axitinib (Figure 1) target the VEGFR-2 signaling pathway and are commonly used in the treatment of cancers such as renal cell carcinoma, hepatocellular carcinoma, and gastrointestinal stromal tumors [9]. The gene discussed is KDR; the disease is cancer.